Marja-liisa Dahl

Prof. Marja-liisa Dahl


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2016 in Substance Abuse Treatment, Prevention, and Policy
Verified
Journal Article
Open access
PDF file
ABAnnica Börjesson
Annica Börjesson
NGNina Gårevik
Nina Gårevik
MDMarja-liisa Dahl
Marja-liisa Dahl
ARAnders Rane
Anders Rane
LELena Ekström
Lena Ekström
Doping with anabolic androgenic steroids in sports has now developed to a widespread use of these agents among young people outside the sport. This is of major concern to the society. The purpose of the use is mainly for aesthetic reasons and is seen as a male phenomenon. But use also occurs in women where the knowledge is scarce. Our aim was to identify the pattern of doping agents in eight female cases and compare them with similar data from men. Eight female users were recruited through Anti-Doping Hot-Line, a national telephone counseling service on doping issues during the years 1998–2004. The use was confirmed with urine doping analysis at the Doping Laboratory. The characteristic of use, co-use of narcotics/other doping agents, exercise pattern, adverse-side effects, family history and reason to begin was evaluated. The women used on average 1.9 different anabolic androgenic steroids and clenbuterol preparations. Ephedrine and growth hormone were co-used in five and one of the women, respectively. Three women reported co-use of narcotics (cannabis and cocaine). The average duration of anabolic agent use before contacting health care was 58 weeks (range 7–104). Side effects for anabolic androgenic steroids (n = 5) included voice changes, clitoral enlargement, body hair growth, whereas women using clenbuterol (n = 2) reported tachycardia and depression. All women except one had a man in close relationship encouraging them to begin with the doping agents. The use of doping agents in our eight women was different from that in male users. The women used less doping agents and were more prone to contact the health care, at an earlier stage, probably due to the adverse effects. The co-use with ephedrine, growth hormone and cannabis appeared to be in the same range as in men. This is the first study showing that a man in close relationship may motivate a woman to use anabolic agents.

28 May 2020 in Medicina
Verified
Journal Article
Open access
PDF file
ABAnnica Börjesson
Annica Börjesson
CMChristian Möller
Christian Möller
AHAnders Hagelin
Anders Hagelin
VVVeronica Vicente
Veronica Vicente
ARAnders Rane
Anders Rane
LELena Ekström
Lena Ekström
Background and objectives: Anabolic androgenic steroids (AAS) are mainly used for aesthetic and performance-enhancing reasons. Their use is a growing public health problem and concern for society because of their adverse effects. The primary aim of this study was to identify psychiatric and personality disorders and to measure anxiety and depression in AAS users. Materials and Methods: Fifty-six males who actively contacted the Anti-Doping Hot-Line and wished to stop using AAS were included. Structured Clinical Interviews Diagnosis-I and -II were used to diagnose psychiatric and personality disorders. The Brief Scale for Anxiety and Montgomery Asberg Depression Rating Scale (subscales from the Comprehensive Psychopathological Rating Scale) were used to measure changes in anxiety and depression. Structured Clinical Interviews Diagnosis-I and -II were performed at one time point. Anxiety and depression were measured at inclusion and after six months. Urine samples were collected for an analysis of AAS and drugs of abuse. Results: All participants reported some adverse effects that they associated with AAS use. In total, 56% and 52% of the cohort fulfilled the criteria for Structured Clinical Interviews Diagnosis-I and -II diagnoses, respectively. A significantly increased risk of reporting aggressive feelings/behaviors (Odds Ratio (OR) = 4.9; Confidence Interval (CI) 0.99–25, p = 0.04), suicidal thoughts/attempts (OR = 4.6, CI 95; 0.99–21, p = 0.04) and criminality (OR = 6.5, CI 1–39, p = 0.03) was found among individuals with AAS use fulfilling the criteria for personality disorders compared with those without such AAS use. The Brief Scale for Anxiety score decreased from the median of 15 at inclusion to 10 at the follow-up visit six months later (p = 0.01, n = 19). Conclusions: Our findings indicate that among individuals with AAS use, those with a personality disorder report more aggressive behaviors, suicidal thoughts/suicidal attempts, and criminality than those without a personality disorder.

27 February 2018 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MEMichel Eichelbaum
Michel Eichelbaum
MDMarja-liisa Dahl
Marja-liisa Dahl
FSFolke Sjöqvist
Folke Sjöqvist

14 June 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MDMarja-liisa Dahl
Marja-liisa Dahl
UBUlf Bergman
Ulf Bergman
LBLeif Bertilsson
Leif Bertilsson
EEErik Eliasson
Erik Eliasson
LGLars L. Gustafsson
Lars L. Gustafsson
ARAnders Rane
Anders Rane